• 6346 Citations
  • 33 h-Index
19982018
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Tommaso De Pas is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Cisplatin Medicine & Life Sciences
Sarcoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2018

  • 6346 Citations
  • 33 h-Index
  • 145 Article
  • 1 Chapter
  • 1 Letter
  • 1 Review article
3 Citations (Scopus)

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer

Toffalorio, F., Santarpia, M., Radice, D., Jaramillo, C. A., Spitaleri, G., Manzotti, M., Catania, C., Jordheim, L. P., Pelosi, G., Peters, G. J., Tibaldi, C., Funel, N., Spaggiari, L., de Braud, F., De Pas, T. & Giovannetti, E., Jan 1 2018, In : Oncotarget. 9, 23, p. 16437-16450 14 p.

Research output: Contribution to journalArticle

gemcitabine
5'-Nucleotidase
Combination Drug Therapy
Platinum
Non-Small Cell Lung Carcinoma

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer

Toffalorio, F., Santarpia, M., Radice, D., Jaramillo, C. A., Spitaleri, G., Manzotti, M., Catania, C., Jordheim, L. P., Pelosi, G., Peters, G. J., Tibaldi, C., Funel, N., Spaggiari, L., de Braud, F., De Pas, T. & Giovannetti, E., Mar 27 2018, In : Oncotarget. 9, 23, p. 16437-16450 14 p.

Research output: Contribution to journalArticle

gemcitabine
5'-Nucleotidase
Combination Drug Therapy
Platinum
Non-Small Cell Lung Carcinoma
5 Citations (Scopus)

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

Forster, M., Hackshaw, A., De Pas, T., Cobo, M., Garrido, P., Summers, Y., Dingemans, A. M. C., Flynn, M., Schnell, D., von Wangenheim, U., Loembé, A. B., Kaiser, R. & Lee, S. M., Jun 1 2018, In : Lung Cancer. 120, p. 27-33 7 p.

Research output: Contribution to journalArticle

gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Lung Neoplasms
Maximum Tolerated Dose
62 Citations (Scopus)

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., Gelber, R. D. & Goldhirsch, A., Jun 1 2018, In : The Lancet Oncology. 19, 6, p. 737-746 10 p.

Research output: Contribution to journalArticle

Immunotherapy
Meta-Analysis
Neoplasms
Survival
Non-Small Cell Lung Carcinoma
11 Citations (Scopus)

Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy

Zucali, P. A., De Pas, T., Palmieri, G., Favaretto, A., Chella, A., Tiseo, M., Caruso, M., Simonelli, M., Perrino, M., De Vincenzo, F., Toffalorio, F., Damiano, V., Pasello, G., Garbella, E., Ali, M., Conforti, F., Ottaviano, M., Cioffi, A., De Placido, S., Giordano, L. & 4 others, Bertossi, M., Destro, A., Di Tommaso, L. & Santoro, A., Feb 1 2018, In : Journal of Clinical Oncology. 36, 4, p. 342-349 8 p.

Research output: Contribution to journalArticle

Thymoma
Cisplatin
Drug Therapy
Everolimus
Disease-Free Survival